Inotuzumab ozogamicin cost effective for acute lymphoblastic leukaemia in Sweden and Norway
Source: PharmacoEconomics and Outcomes News - Category: Drugs & Pharmacology Source Type: news
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Drugs & Pharmacology | Leukemia | Norway Health | Sweden Health